Elekta’s Versa HD radiation therapy system now available for treatment of cancer patients in Japan

        Print
| Source: Elekta AB
Linear accelerator receives clearance from country’s Ministry of Health, Labor
and Welfare
TOKYO, Japan, September 2, 2014 – Cancer care providers in Japan have the
opportunity to strengthen their cancer treatment capacity with the recent
clearance of Elekta’s Versa HD™ by Japan’s Ministry of Health, Labor and
Welfare. Versa HD is an advanced radiation treatment system designed to enhance
the management of cancer care and treat a broad spectrum of tumors throughout
the body. In a single system, Versa HD is capable of delivering conventional
therapies for a wide range of indications commonly seen in the clinic, while
also permitting treatment of complex cancers that require exceptional targeting
accuracy.

The clearance of Versa HD in Japan follows CE marking of the system from the
European Union and 510(k) clearance from the U.S. Food and Drug Administration
(FDA) in 2013.

An official report* put the number of cancer deaths in 2012 in Japan at
approximately 361,000, with the number of male cancer deaths 1.5 times greater
than female cancer deaths. Lung cancer was the most prevalent for men at 24
percent, followed by stomach (15 percent), colorectal (12 percent), liver (9.3
percent) and pancreas (7.2 percent). Among women, the most common cancer was
colorectal at 15 percent, followed by lung (13.8 percent), stomach (11.6
percent), pancreas (10 percent) and breast (8.6 percent).

“The Ministry’s clearance of Versa HD is an important step in addressing serious
increases in cancer incidences and deaths in Japan,” says Shuichi Higaki,
President and Managing Director, Elekta Japan. “With its high precision beam
shaping and tumor targeting technologies – in addition to three times higher
dose rate delivery than our previous treatment systems – Versa HD offers
patients in Japan the chance for a better outcome.”

Learn more at www.VersaHD.com.

*Cancer Statistics in Japan –
2013 (http://ganjoho.jp/data/professional/statistics/backnumber/2013/cancer_stat
i 
stics_2013.pdf). Foundation for Promotion of Cancer Research (FPCR)

Versa HD is not for sale or distribution in all markets.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524, e-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on September 2, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.